Data / Public companies / SIC 2890: Miscellaneous chemical products / Pure Bioscience, Inc.
Pure Bioscience, Inc.: revenue, net income and total assets from its latest annual report
Pure Bioscience, Inc. reported revenue of $2.2 million, a net loss of $2.4 million and total assets of $1.1 million for the fiscal year ended July 31, 2025, in its annual report (10-K) filed with the SEC on October 29, 2025. It ranks 416th by revenue of 522 companies in SIC 28xx, industries with the same first two SIC digits.
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 1006028
- Industry
- SIC 2890, Miscellaneous chemical products
- Business address (city and state)
- El Cajon, California
- Incorporated in
- Delaware
- Filer category
- Non-accelerated filer
- Fiscal year ends
- July 31
- Latest annual report
- 10-K filed October 29, 2025
- Annual and quarterly reports in the data
- 1 annual, 3 quarterly
Financials for the fiscal year ended July 31, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $2,202,000 | $1,963,000 | 12.2% | sec.gov |
| Operating income | $-2,272,000 | Not listed | Not listed | sec.gov |
| Net income | $-2,399,000 | $-3,350,000 | 28.4% | sec.gov |
| Total assets | $1,058,000 | $818,000 | 29.3% | sec.gov |
| Total liabilities | $6,174,000 | Not listed | Not listed | sec.gov |
| Stockholders' equity | $-5,116,000 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $334,000 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -108.9%
- Revenue change on the prior year
- 12.2%
- Revenue rank in SIC 28xx
- 416th of 522
- Revenue rank in California
- 589th of 662
- Revenue rank among all companies in the data
- 4,007th of 4,486
Companies next to it by revenue in SIC 28xx
Industries with the same first two SIC digits, from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Park Ha Biological Technology Co., LTD. | Wuxi City, China | $2.5 million | $-24,364,753 | $6 million | 6% |
| Geovax Labs, Inc. | Smyrna, GA | $2.5 million | $-21,464,771 | $6.3 million | -37.1% |
| Citrotech Inc. | Greenwood Village, CO | $2.4 million | $-36,837,643 | $14.2 million | 194.6% |
| Senestech, Inc. | Phoenix, AZ | $2.2 million | $-6,383,000 | $12.8 million | 19.6% |
| Aligos Therapeutics, Inc. | South San Francisco, CA | $2.2 million | $-24,193,000 | $88.5 million | -39.5% |
| Bonk, Inc. | Jupiter, FL | $2.1 million | $-68,185,762 | $41 million | 201.6% |
| Cyclerion Therapeutics, Inc. | Cambridge, MA | $2.1 million | $-3,528,000 | $10 million | 3.7% |
| Vitro Biopharma, Inc. | Denver, CO | $2.1 million | $-10,851,802 | $4.9 million | 10.8% |
Updated October 29, 2025. Read from SEC Financial Statement Data Sets, filing 0001493152-25-020065. Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.